Month: September 2022

Chartwell Partners is pleased to announce that Helen Kim has joined Prothena’s Board of Directors. Prothena Corporation plc is a public, late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Ms. Kim has over…